Inhibitors of the MEK are frequently used in combination with BRAFi, markedly improving the survival of patients with BRAF-mutant tumors, and this combination is FDA approved for use in BRAFV600E-mutated melanoma (9–11). Here, MAP2K7 is linked to melanoma.